Gait Analysis in Neurological Disease

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Beth Israel Deaconess Medical Center
Study ID
NCT02994719
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Accepted

Interventions

  • Anti-Parkinson medication — DRUG
    During the optional second visit subjects with neurological disease and already on anti-parkinson medication are asked to come off their anti-parkinson medication.
  • Deep Brain Stimulation — DEVICE
    During the optional second visit subjects with neurological disease already treated with deep brain stimulation are asked to come temporarily stop deep brain stimulation and resume stimulation, with walking trials done in each condition.

Study Details

The purpose of this study is to investigate whether speed-dependent measures of gait can be identified in patients with neurological conditions that affect gait, particularly in subjects with parkinsonian disorders.

Key Dates

Start date
Mar 1, 2016
Status verified
Jun 2025
Primary completion
Jun 20, 2026
Completion
Jun 20, 2026

Study Design

Enrollment
120 participants (estimated)

Arms

  • Arm: Neurological Disease subjects
    Parkinson's Disease and other Parkinsonian Disorders subjects. Other Parkinsonian Disorders include Atypical Parkinsonism such as Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Primary Gait Freezing Disorder, Indeterminate Parkinsonian Syndrome. During the first visit no intervention will take place. There is an optional second visit during which subjects with Parkinson's Disease are asked to come come off antiparkinson medication and if applicable, off both medication and deep brain stimulation.
  • Arm: Healthy control subjects
    The healthy control subjects will be age- and sex-matched to the Neurological Disease subjects.
  • Arm: Ataxia Subjects
    The ataxia subjects will participate in an additional cohort that will test and validate the gait model.
  • Arm: Huntington Disease Subjects
    The Huntington Disease subjects will participate in an additional cohort that will test and validate the gait model.

Primary Outcome Measure

Gait speed [ Time Frame: through study completion, an average of 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Clinical Research Center BIDMCBostonMassachusetts02215-

Find similar trials in Boston, MA

By condition
Huntington diseaseParkinson's disease
By specialty
NeurologyBrain disorders
By research site
Clinical Research Center BIDMC· Boston, MA

Related Studies